Q2 2026 Paysign Inc Earnings Call Transcript
Key Points
- PaySign Inc (PAYS) delivered record second-quarter results with revenue up 48% year-over-year to $28.3 million, net income nearly five-fold higher at $6.8 million, and adjusted EBITDA up 113% to $9.6 million.
- Patient Affordability revenue surged 89% year-over-year to $14.6 million, driven by a 54% increase in claim volume and the launch of 13 new programs, bringing the total to 148 active programs.
- The company raised its full-year 2026 guidance, now expecting revenue of $114-$117 million (39%-43% growth) and adjusted EBITDA of $35-$38 million, reflecting strong momentum and visibility.
- Gross margin expanded 170 basis points to 63.3%, with adjusted operating margin improving to 21.3% from 7.5% a year ago, demonstrating significant operating leverage.
- Plasma business showed recovery, with revenue up 21.4% to $13 million and monthly revenue per center reaching $7,699, the highest since Q3 2024, indicating normalized donor activity.
- The company's dynamic business rules technology shielded clients from over $300 million in costs in the first half of 2026, nearly matching the full-year 2025 total, enhancing client value.
- PaySign Inc (PAYS) maintains a strong balance sheet with $27.4 million in cash and zero bank debt, supporting future growth initiatives.
- The pipeline for new programs remains robust, with expectations to match or surpass the 55 net additions in 2025, and the company has established a European hub in Ireland to pursue international growth.
- The company's growth is heavily dependent on the Patient Affordability segment, which could expose it to concentration risk if pharmaceutical partnerships face regulatory or market changes.
- Plasma center count declined to 561 due to 19 center closures, partially offset by only 7 new additions, indicating ongoing consolidation in that segment.
- The Apherion BECS donor management system is still awaiting FDA regulatory approval, with no clear timeline for launch, delaying potential revenue from this high-growth opportunity.
- Operating expenses increased 15.1% (excluding one-time benefits), driven by hiring and investments to support growth, which could pressure margins if revenue growth slows.
- The effective tax rate is expected to rise in Q4 to around 27% from 17% in Q3, due to lower stock-based compensation deductions, potentially impacting net income.
- Seasonal patterns show pharma revenue typically moderates in the second half of the year, which could lead to slower sequential growth despite strong full-year guidance.
- The company's reliance on RFP wins (over 80% win rate) may face competitive pressure as the market for patient affordability solutions becomes more crowded.
- International expansion through Apherion Technologies Limited carries execution risks, including regulatory, cultural, and operational challenges in new markets.
Good afternoon. My name is Kevin. I'll be your conference operator today. At this time, I'd like to welcome everyone to Paysign's second quarter 2026 earnings conference call. After the speaker's remarks, there'll be a question and answer session. If you'd like to be placed into question queue, please press star one on your telephone keypad. As a reminder, this conference call is being recorded. The comments on today's call regarding Paysign's financial results will be on a GAAP basis unless otherwise noted. Paysign's earnings release was disseminated to the SEC earlier today and can be found in the investor relations section of our website, paysign.com, which includes reconciliations of non-GAAP measures to GAAP reported amounts. Additionally, as set forth in more detail in our earnings release, I'd like to remind everyone that today's call will include forward-looking statements regarding Paysign's future performance.
Actual performance could differ materially from these forward-looking statements. Information about the factors that could affect future performance is summarized at the end of
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
